Watanabe Y, Shimizu J, Yoshida Y, Hashizume Y, Yamada T, Iwa T
Department of Surgery, Kanazawa University School of Medicine, Japan.
Nihon Geka Gakkai Zasshi. 1989 Sep;90(9):1432-5.
To evaluate the clinical efficacy of OK-432 immunotherapy, patients admitted between 1975 and 1982 were randomized into two groups: An immunochemotherapy (IM-C) group and a chemotherapy (control) group. For each group, a fixed chemotherapy was administered using a combination of three drugs. The survival rates of cases with non-small cell carcinoma were evaluated at the end of 1987. One hundred and fifty-seven cases in the IM-C group and 148 in the control group were eligible for evaluation of long-term survival rates. Statistically significant improvement of the survival rates in the IM-G group were noted in the following items: All cases, resected cases, non-resected cases, resected stage I + II cases, resected stage III cases, completely resected cases, incompletely resected cases, and cases with epidermoid carcinoma. However, in comparison of adenocarcinoma there was no significant difference between the two groups. SU-polysaccharide skin test and natural killer activity were the best immunological parameters during the OK-432 therapy. To intensify the effects of immunotherapy, a possibility of regional immunotherapy was studied following some experimental works. Regional infusion of LAK cells (induced by incubation of patient's lymphocytes with rIL-2) through bronchial artery after regional infusion of OK-432 and chemotherapeutics showed favorable effect for advanced lung cancer. Future prospect of these regional adoptive immunotherapy was discussed.
为评估溶链菌免疫疗法的临床疗效，将1975年至1982年间收治的患者随机分为两组：免疫化疗（IM-C）组和化疗（对照组）。每组均使用三种药物联合进行固定化疗。1987年底评估非小细胞癌患者的生存率。IM-C组有157例、对照组有148例符合长期生存率评估标准。在以下各项中，IM-C组的生存率有统计学意义的提高：所有病例、切除病例、未切除病例、切除的Ⅰ+Ⅱ期病例、切除的Ⅲ期病例、完全切除病例、不完全切除病例以及表皮样癌病例。然而，腺癌患者两组之间无显著差异。溶链菌治疗期间，SU-多糖皮肤试验和自然杀伤活性是最佳免疫指标。为增强免疫治疗效果，在一些实验工作后研究了区域免疫治疗的可能性。在经支气管动脉局部注入溶链菌和化疗药物后，局部注入LAK细胞（由患者淋巴细胞与重组白细胞介素-2孵育诱导产生）对晚期肺癌显示出良好效果。讨论了这些区域过继性免疫治疗的未来前景。
